Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06950034 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
A Phase 1 study of Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia, sponsored by Solu Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 7
- Study locations
NCT06950034 is a Phase 1 study of Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia that is actively recruiting participants, run by Solu Therapeutics. The registered enrollment target is 105 participants, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The trial reports 7 study locations across 7 states.
The verdict
NCT06950034, a Phase 1 study of Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia, is actively recruiting participants, sponsored by Solu Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.
Conditions Studied
Interventions
- BIOLOGICAL STX-0712
Study Locations (7)
California
- Stanford University - Stanford
Florida
- Moffitt - Tampa
Massachusetts
- DFCI - Boston
Minnesota
- Mayo Clinic - Rochester
Oregon
- OHSU - Portland
Tennessee
- Vanderbilt University - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06950034
The ClinicalTrials.gov registry entry for NCT06950034 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The listed sponsor is Solu Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which STX-0712 is the first listed.
NCT06950034 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06950034 about?
NCT06950034 is a clinical study titled "A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)". This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.
What is the current status of trial NCT06950034?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2025-03-13. Estimated completion is 2027-06-30.
What conditions does trial NCT06950034 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Post Cytotoxic Therapy, Refractory Chronic Myelomonocytic Leukemia.
What interventions are being tested in trial NCT06950034?
The interventions under investigation include: STX-0712 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06950034?
This trial is sponsored by Solu Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06950034 being conducted?
This trial has 7 study locations across California, Florida, Massachusetts, Minnesota, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
RECRUITING · Phase 1
-
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
RECRUITING · Phase 1
-
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
RECRUITING · Phase 1
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.